Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States
- PMID: 37347977
- DOI: 10.3322/caac.21786
Implementation in action: Collaborating on the transition to primary HPV screening for cervical cancer in the United States
Keywords: cervical neoplasms; cytopathology or cytotechnology; gynecologic oncology; obstetrics and gynecology; prevention.
References
REFERENCES
-
- Fontham ETH, Wolf A, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346. doi:10.3322/caac.21628
-
- Franco EL, on behalf of the American Cancer Society Primary HPV Screening Initiative Steering Committee. The time has come for implementing primary human papillomavirus testing for cervical cancer screening in the United States.
-
- Bouvard V, Wentzensen N, Mackie A, et al. The IARC perspective on cervical cancer screening. N Engl J Med. 2021;385(20):1908-1918. doi:10.1056/NEJMsr2030640
-
- US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674-686. doi:10.1001/jama.2018.10897
-
- Schiffman M, Kinney WK, Cheung LC, et al. Relative performance of HPV and cytology components of cotesting in cervical screening. J Natl Cancer Inst. 2018;110(5):501-508. doi:10.1093/jnci/djx225
